Affordable Access

Publisher Website

The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping

Authors
Journal
The Breast
0960-9776
Publisher
Elsevier
Volume
23
Issue
3
Identifiers
DOI: 10.1016/j.breast.2014.02.013
Keywords
  • Breast Cancer
  • Androgen Receptor
  • Taxanes
  • Her2
  • Molecular Apocrine
  • Immunohistochemistry
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Objectives The Androgen Receptor (AR) is a potential prognostic marker and therapeutic target in breast cancer. We evaluated AR protein expression in high-risk breast cancer treated in the adjuvant setting. Materials and methods Tumors were subtyped into luminal (ER+/PgR±/AR±), molecular apocrine (MAC, [ER−/PgR−/AR+]) and hormone receptor negative carcinomas (HR-negative, [ER−/PgR−/AR−]). Subtyping was evaluated with respect to prognosis and to taxane therapy. Results High histologic grade (p < 0.001) and increased proliferation (p = 0.001) more often appeared in MAC and HR-negative than in luminal tumors. Patients with MAC had outcome comparable to the luminal group, while patients with HR-negative disease had increased risk for relapse and death. MAC outcome was favorable upon taxane-containing treatment; this remained significant upon multivariate analysis for overall survival (HR 0.31, 95% CI 0.13–0.74, interaction p = 0.035) and as a trend for time to relapse (p = 0.15). Conclusion AR-related subtyping of breast cancer may be prognostic and serve for selecting optimal treatment combinations.

There are no comments yet on this publication. Be the first to share your thoughts.